Key messagesThe best measure of overall physical function is the 8′UG.The subjective MDHAQ and SF36-PC questionnaires are both relatively poor measures of objectively assessed physical function.The 8′UG and 50′W are appropriate tests for assessing functional status of RA patients in routine clinics.

Introduction
============

RA patients typically experience adverse, inflammatory-driven changes in body composition, which result in muscle wasting and increased fat mass. This condition, termed rheumatoid cachexia (RC) \[[@rkx017-B1]\], is a major contributor to the impaired physical function of these patients \[[@rkx017-B2], [@rkx017-B3]\]. Poor physical function is a strong predictor of clinical outcome in RA, and is associated with increased morbidity and mortality, reduced quality of life and higher treatment costs \[[@rkx017-B4]\]. Both patients and health-care professionals identify physical function as a key outcome in the management of RA \[[@rkx017-B7]\] and improving function as an important therapeutic target in clinical care \[[@rkx017-B6], [@rkx017-B8]\]. Hence, accurate assessment of physical function is required if RA treatment is to be optimized \[[@rkx017-B10]\].

It was reasoned that improvements in disease management, specifically early and aggressive tight pharmaceutical control of inflammation, such as the current treat-to-target (T2T) approach \[[@rkx017-B8]\], would attenuate RC and the associated poor physical function. However, in our recent study of 82 T2T RA patients with well-controlled disease (mean DAS28 of 2.8; 49% in clinical remission) we found that RC and markedly reduced physical function are still apparent \[[@rkx017-B11]\]. Notably, despite these patients rating their disability as being only mild on the Multi-Dimensional HAQ (MDHAQ), strength relative to age- and sex-matched sedentary healthy controls was reduced by ∼25%, and performance of objective physical function tests designed to reflect the ability to perform activities of daily living (ADL) were reduced by approximately a third. Worryingly, on average, these patients with well-controlled disease had the physical function level typical of healthy sex-matched individuals ∼25 years older (based on reference values \[[@rkx017-B12]\]).

Currently, clinical assessment of physical function in RA patients is performed using subjective, self-reported questionnaires, such as the HAQ \[[@rkx017-B13]\] or adaptations of the HAQ (e.g. the MDHAQ \[[@rkx017-B9], [@rkx017-B14], [@rkx017-B15]\]). This has been justified because of the HAQ's reliability, adaptability and ease of use and delivery, and an emphasis on outcomes that are relevant to the patient (i.e. patient-reported outcome measures) \[[@rkx017-B16], [@rkx017-B17]\]. Consequently, the HAQ has become the pre-eminent patient-reported outcome measure in rheumatology \[[@rkx017-B15]\] and is recommended for the routine assessment of physical function by RA management guidelines \[[@rkx017-B9], [@rkx017-B14]\].

However, like most questionnaires, the HAQ suffers from various psychometric limitations; most notably, as it was designed to detect impairment among patients with greater disability than those typically seen today \[[@rkx017-B17], [@rkx017-B18]\], it consequently suffers from floor effects (i.e. normal scores despite physical function impairments) \[[@rkx017-B15]\]. These effects were evident in our recent trial \[[@rkx017-B11]\]. It is also well established that these questionnaires are influenced by age, gender, disease duration, depression, education, social class, ethnicity, personality \[[@rkx017-B10], [@rkx017-B18]\] and, especially, pain \[[@rkx017-B22]\]. Notably, both the HAQ and MDHAQ are insensitive to the large functional gains (including normalization of objectively assessed function), which can result from exercise training \[[@rkx017-B26]\].

Owing to the large number of external influences, it is unsurprising that self-reported function measures often show only weak-to-moderate relationships with objective performance-based tasks in RA patients \[[@rkx017-B11], [@rkx017-B19]\]. This weak-to-moderate association has also been demonstrated in the elderly \[[@rkx017-B29], [@rkx017-B30]\] and in lower back pain \[[@rkx017-B31]\], OA \[[@rkx017-B32]\], AS \[[@rkx017-B33]\] and fibromyalgia patients \[[@rkx017-B34]\]. Along with floor effects \[[@rkx017-B15]\], it has been proposed that the discordance between the HAQ and objective measures occurs because subjective measures evaluate what patients experience when performing activities, rather than their ability to perform these activities \[[@rkx017-B32]\]. As such, objective performance measures contribute information beyond that obtained from self-reported physical function \[[@rkx017-B30]\] and, consequently, objective tests appear to be preferable for assessing real physical function in RA \[[@rkx017-B21]\]. However, along with the lack of recognition and understanding of the relative advantages of objective tests over subjective questionnaires, the limitations of the clinical environment (i.e. time, space, equipment, staff and specific expertise) mitigate against the inclusion of a full battery of objective function tests in routine clinical RA management \[[@rkx017-B35]\]. If objective function testing is to be adopted and routinely used in clinical practice, there needs to be clear guidance on which test provides the best measure of overall physical function.

Thus, the present study aimed to determine: (i) which clinically practicable objective function test best represents overall physical function; and (ii) the extent to which self-reported functional measures reflect objectively assessed function. The identification of the best overall objective physical function test in this study was exploratory and, as such, a hypothesis was not applicable. However, we did hypothesize that self-reported functional status \[HAQ and SF-36 physical component (SF36-PC)\] would not correlate strongly with function as indicated by objective tests.

Methods
=======

Study population
----------------

Patients with well-controlled, stable RA were recruited from outpatient clinics of the Peter Maddison Rheumatology Centre, North Wales. For inclusion, participants had to: fulfil the ACR 2010 revised criteria for RA \[[@rkx017-B36]\]; be aged ≥18 years; not be cognitively impaired; be free of other cachectic diseases or conditions; not be taking anabolic drugs or nutritional supplements; and not be pregnant. All patients were diagnosed after 1 January 2008 and had been exclusively treated using contemporary treatment strategies (T2T). This patient cohort was recruited for a cross-sectional study that evaluated the effect of tight control of disease activity on body composition and physical function in RA patients \[[@rkx017-B11]\]. The study was approved by the North Wales Research Ethics Committee-West (12/WA/0323), and conducted in compliance with the Declaration of Helsinki.

Assessments and outcome measures
--------------------------------

All outcome measures and protocols have been previously described in detail \[[@rkx017-B11]\], so are only briefly summarized here.

### Physical function

Maximal isometric knee extensor strength (IKES) was measured using an isokinetic dynamometer (Humac Cybex Norm 2004; Computer Sports Medicine Inc., MA, USA), and maximal handgrip strength (HGS) by a Grip-A dynamometer (Takei Kiki Kogyo, Japan). Objective function was also assessed by three tests specifically developed to evaluate the ability of older adults to perform ADLs \[[@rkx017-B12]\]: sit-to-stands in 30 s (STS-30), 8-foot up and go (8′UG) and 50-foot walk (50′W). Aerobic capacity (V̇O~2~max) was estimated using the progressive submaximal Siconolfi step test \[[@rkx017-B37]\]. This test has been validated in RA \[[@rkx017-B38]\]. Performance of each of these tests was preceded by a submaximal practice. Our group routinely uses these tests to assess physical function in RA \[[@rkx017-B11], [@rkx017-B27], [@rkx017-B28], [@rkx017-B38], [@rkx017-B39]\]. In order to promote inclusion into routine clinical assessments, a full step-by-step guide for delivery of each of the objective tests described here can be found in the [supplementary data](#sup1){ref-type="supplementary-material"} available at *Rheumatology Advances in Practice* online.

Subjective physical function was evaluated by the MDHAQ (scored 0--3, with higher scores denoting poorer function) as described by Pincus *et al.* \[[@rkx017-B15]\]. The MDHAQ was used because of notable limitations of the HAQ in well-controlled RA patients; owing to its broader measurement range, this version of the HAQ has been recommended for use in patients with relatively good functional capacity, such as those in the present study \[[@rkx017-B15], [@rkx017-B17]\]. We also used the physical component of the SF36-PC questionnaire (scored 0--100, with lower scores denoting poorer function) \[[@rkx017-B40]\]. The SF36-PC is the most frequently used generic scale of physical function in patients with RA \[[@rkx017-B17]\].

### Clinical measures

Disease activity was assessed by the DAS28, using CRP as the marker of systemic inflammation.

Statistical analysis
--------------------

Pearson's product--moment correlation coefficient (Pearson's *r*) was used to assess the relationships between variables of interest. The correlation coefficient was measured on a scale from −1 through 0 to 1. Complete correlation between two variables is expressed by either −1 or 1, whereas complete absence of correlation is represented by 0 \[[@rkx017-B41]\]. If a variable increases concurrently with another the correlation is positive, whereas when one variable decreases as the other increases the correlation is negative. Correlation strengths were defined according to the following criteria \[[@rkx017-B41]\]: weak: *r* = 0.200--0.399; moderate: *r* = 0.400--0.599; and strong: *r = *0.600--1.00.

In order to quantify the best overall measure of objective physical function, correlations (*r*) between each of the objective tests were averaged for each measure (e.g. each individual *r* value between the 8′UG and the rest of the objective tests (i.e. IKES, HGS, STS-30, 50′W and estimated V̇O~2~max) were averaged to determine a mean *r* for 8′UG. To reduce skew in the *r* distribution \[[@rkx017-B42]\], *r* values were first transformed into normally distributed Fisher *ɀ* values (*ɀ*′) using an established formula: $$ɀ^{\prime} = 0.5{{In}\frac{1 + r}{1 - r}},$$ where ln is the natural logarithm function.

Following conversion to *ɀ*′, these values were averaged (as above) before the mean *ɀ*′ value was back-converted to a final *r* value (*r~ɀ~*~′~) $\prime$using the inverse formula \[[@rkx017-B42]\]: $$r_{ɀ\prime} = ~\frac{{exp}^{2ɀ\prime} - r}{{exp}^{2ɀ\prime} + r},$$ where exp is the exponential.

Subjective measures of physical function (i.e. MDHAQ and SF36-PC) were correlated with objective measures only, using the same *r~ɀ~*~′~ calculation as described above. To avoid confusion in the Results, the final summed and transformed correlation for each test (i.e. *r*~ɀ′~) is presented as an *r* value. Significance was set at *P *\< 0.05. Data were analysed using IBM SPSS Statistics 24, and are presented as means ([s]{.smallcaps}.[d]{.smallcaps}.).

Results
=======

Patients
--------

Patient characteristics and mean physical function data for the 82 RA patients are shown in [Table 1](#rkx017-T1){ref-type="table"}. Full patient demographic data are reported by Lemmey *et al.* \[[@rkx017-B11]\]. T[able]{.smallcaps} 1Patient characteristicsCharacteristicMales (*n *= 29)Females (*n *= 53)Combined (*n *= 82)Age, years65.0 (7.8)58.6 (12.9)60.9 (11.7)Disease duration, months23 (18)24 (20)24 (19)DAS282.7 (1.2)2.9 (0.9)2.8 (1.0)Objective physical function IKES, N474 (131)328 (116)380 (140) HGS, kg34.0 (9.6)21.9 (5.8)26.5 (8.8) STS-30 (repetitions)11.7 (4.2)12.1 (3.3)12.0 (3.6) 8′UG, s7.8 (5.6)7.2 (2.6)7.4 (3.9) 50′W, s11.0 (7.9)10.6 (3.1)10.7 (5.3) V̇O~2~max, ml/kg/min26.0 (7.0)21.4 (5.2)22.9 (6.2)Subjective physical function MDHAQ (0--3)0.64 (0.64)0.53 (0.47)0.57 (0.54) SF36-PC (0--100)42 (11)43 (10)43 (10)[^1]

Correlations between objective and subjective physical function measures
------------------------------------------------------------------------

[Table 2](#rkx017-T2){ref-type="table"} displays the averaged correlations between each measure of function and the remaining objective function measures. In rank order of size, they were as follows: 8′UG: *r* = 0.650; 50′W: *r* = 0.636; IKES: *r* = 0.502; HGS: *r* = 0.449; STS-30: *r* = 0.432; and V̇O~2~max: *r* = 0.358. Although *r* values varied between males and females, 8′UG and 50′W, in that order, were the best measures of overall function (i.e. highest averaged *r* values) for both sexes, as well as for the total patient cohort. For male patients and for all patients combined, the average correlation for both 8′UG and 50′W were rated strong. Averaged correlations (male, female and combined) for IKES, HGS and STS-30 were all rated as moderate. In contrast, for both sexes and when all patients were combined, estimated V̇O~2~max was only weakly associated with the other function measures. T[able]{.smallcaps} 2Averaged correlations for all objective and subjective physical function measures against the objective function measures![](rkx017t2.jpg)[^2]

The MDHAQ was also only weakly correlated with the objective physical function measures (*r* = 0.361). Although the SF36-PC performed better, with a moderate averaged *r* value of 0.415 ([Table 2](#rkx017-T2){ref-type="table"}), its average *r* was still lower than for any of the objective tests (with the exception of the submaximal V̇O~2~max step test).

Full individual correlation analysis for the total group, and for males and females, is shown in [Table 3](#rkx017-T3){ref-type="table"}. T[able]{.smallcaps} 3Correlates between physical function measures (objective and subjective) in all RA patients, male RA patients and female RA patients![](rkx017t3.jpg)[^3]

Discussion
==========

Poor physical function is a strong predictor of clinical outcome in RA \[[@rkx017-B4], [@rkx017-B5]\], and accurate assessment of function is an essential part of RA management \[[@rkx017-B10]\]. We have shown that overall objective physical function, as determined by a battery of objective function tests, is best represented by the 8′UG test followed by the 50′W. Both these tests, in male and female patients, as well as for the RA patient cohort overall, showed moderate to strong correlations with each of the other objective function tests considered. Additionally, our results show that the routine, recommended, subjective self-reported measures (e.g. MDHAQ, SF36-PC) are not representative of objectively assessed physical function.

Both the 8′UG and 50′W tests are simple to perform, require minimal equipment (i.e. markers on the floor and, in the case of the 8′UG, a standardized chair) and are easy to explain to patients. Each test is scored as time taken to complete the task (in seconds), and thus, only additionally requires a stopwatch. Both tests only take a couple of minutes to explain, and for patients to practice, and then take \<1 min to perform. Unpublished observations by our group found inter-rater reliability for the 8′UG to be excellent (intraclass correlation coefficient, ICC = 0.972) and for the 50′W to be good (ICC = 0.704). Therefore, provided established protocols are followed \[[@rkx017-B12]\] (see [supplementary material](#sup1){ref-type="supplementary-material"} 1, available at *Rheumatology Advances in Practice* online), any confounding effect of administration and scoring by different health-care professionals is small.

Although the 8′UG and 50′W were highly correlated with each other, and both performed well in comparison with the other objective function tests, we found that the 8′UG consistently demonstrated the best correlation. This is likely to be because the 8′UG requires a range of physical abilities, including lower body strength, dynamic balance, walking ability, agility and gait speed \[[@rkx017-B12], [@rkx017-B43]\]. It also replicates an ADL patients would be required to perform several times a day (e.g. getting up from a chair to answer the telephone, go to the toilet, answer the front door, etc.). Although the 50′W may be more appropriate for some patients (e.g. those with difficulties getting out of a chair), its key limitation is the requirement for an appropriate and safe location to perform the test (i.e. a straight corridor of at least 25 feet (there and back test) free of hospital or clinic traffic). As such, especially in smaller locations, such as outpatient clinic rooms, we recommend the 8′UG for assessing objective physical function in RA patients.

In our trial, the Siconolfi step test was used to estimate cardiorespiratory fitness (i.e. V̇O~2~max). In general, this measure was poorly correlated with the other tests of physical function, which aim to reflect the ability of individuals to perform ADLs. However, as the other objective tests used were of relatively short duration (maximum of 30 s continuous physical effort for the STS-30), they are not as reliant on aerobic capacity to complete. Nevertheless, although the Siconolfi step test is not the preferred objective test for assessing disability, this test should not be overlooked. It is well established that RA patients have low aerobic capacity \[[@rkx017-B44]\], and poor V̇O~2~max is associated with an adverse cardiovascular profile (e.g. blood pressure, insulin resistance, high-density lipoprotein) and increased 10-year cardiovascular disease risk in RA \[[@rkx017-B45]\]. Consequently, the sub-maximal Siconolfi step test, a valid and reproducible measure of V̇O~2~max in RA \[[@rkx017-B38]\], is a useful means of evaluating a key cardiovascular disease risk factor, namely aerobic capacity, in RA patients.

We found a discordance between subjective and objective measures of physical function. In particular, the MDHAQ was only weakly associated with objective measures. The HAQ is the recommended measure of physical function in current RA management \[[@rkx017-B9], [@rkx017-B13]\]. However, the self-reported nature of the HAQ means that it is influenced by many external factors, such as age and sex \[[@rkx017-B10], [@rkx017-B18]\] and, especially, pain \[[@rkx017-B22]\]. Furthermore, the HAQ was originally intended to detect much larger functional deficits than those typically seen in the well-controlled patients of today \[[@rkx017-B18]\] and, as such, floor effects (i.e. normal scores despite limited function) are observed \[[@rkx017-B15], [@rkx017-B17], [@rkx017-B18], [@rkx017-B21]\]. The development of the MDHAQ was claimed to reduce these floor effects by 13% compared with the original HAQ \[[@rkx017-B15]\], making it more suitable for patients with well-controlled disease and relatively better physical function \[[@rkx017-B17]\]. However, previous findings by our group (i.e. mild physical function score on the MDHAQ, but substantial objective functional deficits in well-treated current patients) indicate that floor effects persist in the MDHAQ \[[@rkx017-B11]\].

Previous research into the relationship between subjective and objective measures in RA has shown large discordance between the HAQ and the observed ability of patients to perform tasks in the HAQ (e.g. tying shoelaces, doing up buttons) \[[@rkx017-B19]\]. Objective function tests also correlate better with joint damage. Arvidson *et al.* \[[@rkx017-B21]\] found that grip strength, walking capability and the ability to get out of a chair were strongly associated with radiographic joint damage (assessed by the modified Larsen score), whereas no correlation was found between Larsen and HAQ scores. Not surprisingly, these authors concluded that objective functional tests are preferable to HAQ for assessing physical function in RA patients.

Additionally, in the assessment of physical function, it is also important that the measure used is sufficiently sensitive to detect changes after treatment or intervention. Although self-reported physical function (e.g. the HAQ) generally shows improvement when a patient responds to pharmaceutical treatment (especially when the patient initially has uncontrolled disease activity), this response is strongly influenced by the reduction in pain that usually accompanies reduced inflammation \[[@rkx017-B25]\] and may not necessarily reflect improvement in physical function capacity. Conversely, it is known that in patients with controlled RA, the HAQ and MDHAQ are insensitive to the large objective functional gains (including normalization of function) that result from high-intensity exercise training \[[@rkx017-B26]\]. Consequently, it is important that objective, rather than subjective self-reported, measures are used to assess intervention-derived functional improvements in patients with stable RA.

As stated, the HAQ and MDHAQ have notable deficiencies, including floor effects \[[@rkx017-B11], [@rkx017-B15]\], considerable confounding factors \[[@rkx017-B10], [@rkx017-B18], [@rkx017-B23], [@rkx017-B24]\] and an inability to detect functional impairment in well-controlled patients \[[@rkx017-B17], [@rkx017-B18]\] or identify changes after exercise training \[[@rkx017-B26], [@rkx017-B28]\]. Nevertheless, the HAQ is recommended by international guidelines \[[@rkx017-B9], [@rkx017-B14]\] and the literature \[[@rkx017-B16]\] and remains the cornerstone of functional assessment in routine RA management because of its high internal consistency, test--retest reliability, responsiveness to change in disease activity \[[@rkx017-B17]\] and, from the clinician's perspective, limited need for training and quick ease of delivery and evaluation \[[@rkx017-B15], [@rkx017-B16]\]. Despite the shortcomings of subjective measures, the patient perception of physical function is an important component of medical care, as greater perceived difficulty in performing functional tasks is associated with poorer global and psychological status, dissatisfaction, reduced quality of life, loss of independence and mortality \[[@rkx017-B15], [@rkx017-B16], [@rkx017-B30]\].

In comparison to the MDHAQ, we found that the SF36-PC was a marginally better indicator of overall objective physical functioning. In addition, the full SF36 has the ability to measure mental health (not measured here) and may be more relevant in assessing the economic impacts (i.e. via quality-adjusted life-years) of treatment \[[@rkx017-B46]\], which may be particularly pertinent to RA, where expensive biologic treatment is frequently used. Nonetheless, although the SF36-PC may be a more accurate depiction of physical function than the HAQ in RA, it is unlikely to be widely adopted into routine rheumatology practice for the following reasons: (i) it is a generic instrument, whereas the HAQ and its derivatives are RA specific \[[@rkx017-B17]\]; (ii) there are expensive annual licence fees for software and the questionnaire itself \[[@rkx017-B47]\]; and (iii) relative to the HAQ, evaluating the SF36-PC is arduous and requires specialized scoring software.

The lack of agreement between objectively and subjectively assessed function reported in RA \[[@rkx017-B19], [@rkx017-B21]\], the elderly \[[@rkx017-B29], [@rkx017-B30]\] and other rheumatic conditions, including back pain, OA, AS and FM \[[@rkx017-B33]\], may arise from inaccurate reporting, limited response criteria and/or measurement error or, alternatively, because performance-based measures may not assess all aspects that influence a participant's subjective functional assessment of that task \[[@rkx017-B30]\]. Accordingly, because objective and subjective measures provide information on different aspects of physical function \[[@rkx017-B21], [@rkx017-B32]\], they may be complementary and, in combination, should provide a more comprehensive understanding of a person's functional status \[[@rkx017-B30]\]. However, owing to the numerous deficiencies of subjective measures, an objective measure should routinely be assessed.

A limitation of the present study is the largely homogeneous cohort assessed. Patients were generally well controlled \[mean DAS28-CRP ([s]{.smallcaps}.[d]{.smallcaps}.) = 2.8 (1.0), 49% in remission\] and, in this regard, our finding that the 8′UG is the most appropriate function test may only be applicable to patients with stable and generally low disease activity. Although the 8′UG remains a potentially feasible and practical test for patients with high disease activity to perform, additional research should confirm whether this test is also the best overall measure of physical function in this group of patients. Future research could also investigate relevant cut-off points for objective physical function performance in RA patients. Previous work in the elderly \[[@rkx017-B30], [@rkx017-B48]\] and other clinical populations, such as Parkinson's disease \[[@rkx017-B43]\] and diabetic peripheral neuropathy \[[@rkx017-B49]\], has shown that 8′UG cut-offs can accurately predict functional mobility skills (e.g. getting into a shower) and fall risk.

Conclusion
----------

Our results show that the 8′UG, followed by the 50′W, demonstrate the strongest correlations with other measures of physical function. Consequently, the 8′UG appears to be the most appropriate objective assessment to assess overall physical function of patients with RA. We found a discordance between function measured by objective tests and that measured subjectively by the MDHAQ and SF36-PC questionnaires. Consequently, in clinical practice, the addition of an objective measure, such as the 8′UG, which is simple and quick to perform, is advocated for determining a patient's real physical function, and may provide a more accurate and comprehensive picture of a patient's functional status.
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[^1]: Data are presented as means ([s]{.smallcaps}.[d]{.smallcaps}.). HGS: handgrip strength; IKES: isometric knee extensor strength; MDHAQ: multi-dimensional HAQ; SF36-PC: short-form 36 questionnaire physical component; STS-30, sit-to-stand in 30 s; 8′UG: 8-foot up and go; V̇O~2~max: estimated aerobic capacity from Siconolfi step test \[data from 62 out of 82 RA patients (*n* = 20 unable to complete test: male (*n* = 9), female (*n* = 11)\]; 50′W: 50-foot walk.

[^2]: Data are presented as correlations between variables (Pearson's *r*). Light grey shading indicates moderate correlations (*r* = 0.400--0.599), and dark grey shading indicates strong correlations (*r* = 0.600)--1.00. (\#) = rank of size for objective measures. HGS: handgrip strength; IKES: isometric knee extensor strength; MDHAQ: multi-dimensional HAQ; SF36-PC: short-form 36 questionnaire physical component; STS-30: sit-to-stand in 30 s; 8′UG: 8-foot up and go; V̇O~2~max: estimated aerobic capacity from Siconolfi step test; 50′W: 50-foot walk.

[^3]: Data are presented as correlations between variables (Pearson's *r*). Light grey shading indicates moderate correlations (*r* = 0.400--0.599), and dark grey shading indicates strong correlations (*r* = 0.600--1.00). \**P* \< 0.05. \*\**P* \< 0.001. Significant correlations are in bold. HGS: handgrip strength; IKES: isometric knee extensor strength; MDHAQ: multi-dimensional HAQ; SF36-PC: short-form 36 questionnaire physical component; STS-30: sit-to-stand in 30 s test; 8′UG : 8-foot up and go; V̇O~2~max: estimated aerobic capacity from Siconolfi step; 50′W: 50-foot walk.
